Experimenta; and clinical studies ont eh effect os terminalia arjuna in hy6perlipdemia

H. P. Shaila, A. L. Udupa, S. L. Udupa

Research output: Contribution to journalArticle

Abstract

The increasing morbidity and mortality from coronary heart disease is the biggest challenge to nutritionists and medical scientists all over the world. There is no single etiology to this multifaceted problem. Certain risk factors have been identified, elevated serum lipids bein the most important. The indigenous drug T. ar.juna when administered alon with cholesterol to rabbits, was round to decrease serum cholesterol, LDL-C, VLDL-C, TG and glucose levels significantly. However, the impact of the drug was most in lowering tissue cholesterol levels (70.6% in liver, 75.6% in heart and 47.6% in aorta cholesterol levels).Histopathological examination of aorta showed reression of atherosclerotic plaque size. In hvoerlipidemic patients with hypertension treated with T. arjuna capsules for 3 months, a significant decrease in serum cholesterol, LDL-C, VLDL-C and LCAT levels was observed, along with an increase in Apo AI and HDL-C levels.The blood pressure of these patients was also lowered. From these data it could be suggested that T. ar.juna may have potential as a hypolipidemic, hypoglycemic and antihypertensive agent and raay afford protection aainst' the development of atherosclerosis.

Original languageEnglish
JournalFASEB Journal
Volume11
Issue number9
Publication statusPublished - 01-12-1997
Externally publishedYes

Fingerprint

Terminalia arjuna
Terminalia
clinical trials
Cholesterol
cholesterol
aorta
low density lipoprotein cholesterol
LDL Cholesterol
antilipemic agents
Aorta
Serum
hypoglycemic agents
Hypolipidemic Agents
drugs
antihypertensive agents
Nutritionists
nutritionists
Apolipoprotein A-I
Blood pressure
Atherosclerotic Plaques

All Science Journal Classification (ASJC) codes

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Shaila, H. P. ; Udupa, A. L. ; Udupa, S. L. / Experimenta; and clinical studies ont eh effect os terminalia arjuna in hy6perlipdemia. In: FASEB Journal. 1997 ; Vol. 11, No. 9.
@article{de671c4c75534ae19542a16b0ceb1514,
title = "Experimenta; and clinical studies ont eh effect os terminalia arjuna in hy6perlipdemia",
abstract = "The increasing morbidity and mortality from coronary heart disease is the biggest challenge to nutritionists and medical scientists all over the world. There is no single etiology to this multifaceted problem. Certain risk factors have been identified, elevated serum lipids bein the most important. The indigenous drug T. ar.juna when administered alon with cholesterol to rabbits, was round to decrease serum cholesterol, LDL-C, VLDL-C, TG and glucose levels significantly. However, the impact of the drug was most in lowering tissue cholesterol levels (70.6{\%} in liver, 75.6{\%} in heart and 47.6{\%} in aorta cholesterol levels).Histopathological examination of aorta showed reression of atherosclerotic plaque size. In hvoerlipidemic patients with hypertension treated with T. arjuna capsules for 3 months, a significant decrease in serum cholesterol, LDL-C, VLDL-C and LCAT levels was observed, along with an increase in Apo AI and HDL-C levels.The blood pressure of these patients was also lowered. From these data it could be suggested that T. ar.juna may have potential as a hypolipidemic, hypoglycemic and antihypertensive agent and raay afford protection aainst' the development of atherosclerosis.",
author = "Shaila, {H. P.} and Udupa, {A. L.} and Udupa, {S. L.}",
year = "1997",
month = "12",
day = "1",
language = "English",
volume = "11",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "9",

}

Experimenta; and clinical studies ont eh effect os terminalia arjuna in hy6perlipdemia. / Shaila, H. P.; Udupa, A. L.; Udupa, S. L.

In: FASEB Journal, Vol. 11, No. 9, 01.12.1997.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Experimenta; and clinical studies ont eh effect os terminalia arjuna in hy6perlipdemia

AU - Shaila, H. P.

AU - Udupa, A. L.

AU - Udupa, S. L.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - The increasing morbidity and mortality from coronary heart disease is the biggest challenge to nutritionists and medical scientists all over the world. There is no single etiology to this multifaceted problem. Certain risk factors have been identified, elevated serum lipids bein the most important. The indigenous drug T. ar.juna when administered alon with cholesterol to rabbits, was round to decrease serum cholesterol, LDL-C, VLDL-C, TG and glucose levels significantly. However, the impact of the drug was most in lowering tissue cholesterol levels (70.6% in liver, 75.6% in heart and 47.6% in aorta cholesterol levels).Histopathological examination of aorta showed reression of atherosclerotic plaque size. In hvoerlipidemic patients with hypertension treated with T. arjuna capsules for 3 months, a significant decrease in serum cholesterol, LDL-C, VLDL-C and LCAT levels was observed, along with an increase in Apo AI and HDL-C levels.The blood pressure of these patients was also lowered. From these data it could be suggested that T. ar.juna may have potential as a hypolipidemic, hypoglycemic and antihypertensive agent and raay afford protection aainst' the development of atherosclerosis.

AB - The increasing morbidity and mortality from coronary heart disease is the biggest challenge to nutritionists and medical scientists all over the world. There is no single etiology to this multifaceted problem. Certain risk factors have been identified, elevated serum lipids bein the most important. The indigenous drug T. ar.juna when administered alon with cholesterol to rabbits, was round to decrease serum cholesterol, LDL-C, VLDL-C, TG and glucose levels significantly. However, the impact of the drug was most in lowering tissue cholesterol levels (70.6% in liver, 75.6% in heart and 47.6% in aorta cholesterol levels).Histopathological examination of aorta showed reression of atherosclerotic plaque size. In hvoerlipidemic patients with hypertension treated with T. arjuna capsules for 3 months, a significant decrease in serum cholesterol, LDL-C, VLDL-C and LCAT levels was observed, along with an increase in Apo AI and HDL-C levels.The blood pressure of these patients was also lowered. From these data it could be suggested that T. ar.juna may have potential as a hypolipidemic, hypoglycemic and antihypertensive agent and raay afford protection aainst' the development of atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=33750281871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750281871&partnerID=8YFLogxK

M3 - Article

VL - 11

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 9

ER -